ReviewAdvances in experimental medicine and biology2025
Myelofibrosis: Timing of Transplantation and Management of Splenomegaly.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment option for patients with myelofibrosis. Because of inherent risk of the procedure, optimal timing in the course of the disease is crucial in order to balance risk and benefit. Besides optimal timing, reducing spleen size-a hallmark of the disease-is needed to ensure timely and sufficient engraftment after HSCT.Disease- and transplant-specific risk scores have been developed to predict the outcome of myelofibrosis with (MTSS) and without transplantation (DIPSS, MIPSS, and MYSEC), and current recommendation is to offer HSCT in primary or secondary myelofibrosis patients up to 70 years of age with intermediate-2 or high-risk DIPSS or MYSEC score or high risk according to MIPSS70 and a low or intermediate risk according to MTSS. Regarding the spleen size, the current European recommendation is for patients with splenomegaly greater than 5 cm below the lower costal margin or splenomegaly-related symptoms to receive a spleen-directed treatment, ideally with JAK-inhibitor and in case of resistance to use second-generation JAK inhibitor or spleen irradiation close to the transplant or splenectomy.
Indexed as
Identifiers
40488829What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.